Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totaling 1,116,504 shares, a growth of ∞ from the May 31st total of 0 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 838,555 shares, the days-to-cover ratio is currently 1.3 days.
Insider Transactions at Parabilis Medicines
In related news, Director Alan Sebulsky purchased 12,500 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at approximately $250,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Guy Levy acquired 500,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the insider directly owned 1,027,000 shares in the company, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 530,000 shares of company stock valued at $10,723,528 over the last quarter.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Parabilis Medicines to a “hold” rating in a research note on Saturday, June 20th.
Parabilis Medicines Trading Up 1.3%
NASDAQ:PBLS traded up $0.36 on Wednesday, hitting $27.73. The stock had a trading volume of 191,347 shares, compared to its average volume of 1,065,125. Parabilis Medicines has a 1 year low of $24.51 and a 1 year high of $34.47.
Featured Articles
- Five stocks we like better than Parabilis Medicines
- Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases
- Comcast’s NBCUniversal Split Puts Broadband Back in Focus
- 3 European Stocks to Carry Investors Through the Back Half of 2026
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
